GHAPP PBC Podcast Series Part 2: New Therapeutics In The PBC Space

Welcome back to Part 2 of our three-part Primary Biliary Cholangitis (PBC) miniseries, where we explore the latest advancements in PBC treatment and disease management. In this episode, Elizabeth Goacher, FNP, Jeremy Davis, NP, and Allison Moser, NP discuss new therapeutic options, including seladelpar and elafibranor, and how these emerging treatments are transforming the PBC landscape.

With the approval of seladelpar and elafibranor, clinicians now have more tools to not only lower alkaline phosphatase (ALP) levels but also to improve cholestatic pruritus, a debilitating symptom that has long remained difficult to manage. Our experts share insights on how these new therapies are addressing both biochemical and symptomatic aspects of PBC, creating a more comprehensive approach to patient care.

This discussion also highlights key considerations for integrating these second-line PBC therapies into clinical practice, including insurance approvals, specialty pharmacy access, and patient support programs that are helping to streamline the prescribing process. The conversation delves into real-world experiences with initiating treatment, the challenges of prior authorizations, and how pharmaceutical support programs are making it easier for patients to access these breakthrough medications.

Watch now to learn how new therapies are shaping the future of PBC management and stay tuned for Part 3 of this series! For more resources, visit the GHAPP website or download the GHAPP ACE app.